Literature DB >> 32119885

Genetic causes of PD: A pathway to disease modification.

M Toffoli1, S R L Vieira1, A H V Schapira2.   

Abstract

The underline neuropathology of Parkinson disease is pleiomorphic and its genetic background diverse. Possibly because of this heterogeneity, no effective disease modifying therapy is available. In this paper we give an overview of the genetics of Parkinson disease and explain how this is relevant for the development of new therapies. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease modifying; GBA1; Genetics; LRRK2; Parkinson disease; SNCA; Therapy

Mesh：

Substances：

Year:  2020        PMID： 32119885     DOI： 10.1016/j.neuropharm.2020.108022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  10 in total

1.  Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology.

Authors:  Qianqian Cao; Shilin Luo; Wei Yao; Youge Qu; Nanbu Wang; Jian Hong; Shigeo Murayama; Zhentao Zhang; Jiaxu Chen; Kenji Hashimoto; Qi Qi; Ji-Chun Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-01       Impact factor: 10.183

2.  Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review.

Authors:  Farzad Salehpour; Michael R Hamblin
Journal:  Biomolecules       Date:  2020-04-15

Review 3.  Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.

Authors:  Loredana Leggio; Greta Paternò; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Gabriele Raciti; Fabrizio Pappalardo; Carmela Giachino; Salvatore Caniglia; Maria Francesca Serapide; Bianca Marchetti; Nunzio Iraci
Journal:  Biomolecules       Date:  2020-09-16

4.  Early-Onset Parkinson Disease Screening in Patients From Nigeria.

Authors:  Lukasz M Milanowski; Olajumoke Oshinaike; Benjamin J Broadway; Jennifer A Lindemann; Alexandra I Soto-Beasley; Ronald L Walton; Rana Hanna Al-Shaikh; Audrey J Strongosky; Fabienne C Fiesel; Owen A Ross; Wolfdieter Springer; Shamsideen Abayomi Ogun; Zbigniew K Wszolek
Journal:  Front Neurol       Date:  2021-01-14       Impact factor: 4.003

Review 5.  Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Authors:  Philipp Mahlknecht; Kathrin Marini; Mario Werkmann; Werner Poewe; Klaus Seppi
Journal:  Transl Neurodegener       Date:  2022-02-21       Impact factor: 8.014

Review 6.  Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease.

Authors:  Matthew K Boag; Angus Roberts; Vladimir N Uversky; Linlin Ma; Des R Richardson; Dean L Pountney
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

7.  Genomic, transcriptomic, and metabolomic profiles of hiPSC-derived dopamine neurons from clinically discordant brothers with identical PRKN deletions.

Authors:  Holly N Cukier; Hyunjin Kim; Anthony J Griswold; Simona G Codreanu; Lisa M Prince; Stacy D Sherrod; John A McLean; Derek M Dykxhoorn; Kevin C Ess; Peter Hedera; Aaron B Bowman; M Diana Neely
Journal:  NPJ Parkinsons Dis       Date:  2022-06-29

Review 8.  Gene-Based Therapeutics for Parkinson's Disease.

Authors:  Karim E Shalaby; Omar M A El-Agnaf
Journal:  Biomedicines       Date:  2022-07-26

9.  High-Resolution Respirometry Reveals MPP+ Mitochondrial Toxicity Mechanism in a Cellular Model of Parkinson's Disease.

Authors:  Pierpaolo Risiglione; Loredana Leggio; Salvatore A M Cubisino; Simona Reina; Greta Paternò; Bianca Marchetti; Andrea Magrì; Nunzio Iraci; Angela Messina
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

Review 10.  The Genetics of Parkinson's Disease and Implications for Clinical Practice.

Authors:  Jacob Oliver Day; Stephen Mullin
Journal:  Genes (Basel)       Date:  2021-06-30       Impact factor: 4.096
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.